| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.IJANTIMICAG.2007.08.016 |
| P698 | PubMed publication ID | 18029150 |
| P2093 | author name string | Peter Ball | |
| P304 | page(s) | S139-41 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | International Journal of Antimicrobial Agents | Q15724616 |
| P1476 | title | Conclusions: the future of antimicrobial therapy - Augmentin and beyond | |
| P478 | volume | 30 Suppl 2 |
| Q42535527 | A lack of synergy between membrane-permeabilizing cationic antimicrobial peptides and conventional antibiotics |
| Q52655525 | Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens? |
| Q33876556 | Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics |
| Q51698927 | Are nonlethal targets useful for developing novel antimicrobials? |
| Q38371796 | Bacterial responses to antibiotics and their combinations |
| Q33871101 | Multidrug evolutionary strategies to reverse antibiotic resistance |
| Q37324603 | Novel approaches to discovery of antibacterial agents |
| Q55398522 | Total Syntheses of Bulgecins A, B, and C and Their Bactericidal Potentiation of the β-Lactam Antibiotics. |
| Q42246515 | Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. |
Search more.